Previous 10 | Next 10 |
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies 2021 Virtual Healthcare Conference. Management is sche...
Oxford Finance announces the closing of a $125M senior secured term loan with Kala Pharmaceuticals ([[KALA]] -0.1%).Proceeds from the transaction will be used to refinance existing indebtedness and provide additional growth capital for the company’s marketing of its two approved ophtha...
Gainers: Stealth BioTherapeutics (MITO) +45%, Biofrontera (BFRA) +18%, BioCryst Pharmaceuticals (BCRX) +15%, Orgenesis (ORGS) +12%, GT Biopharma (GTBP) +4%.Losers: Regional Health Properties (RHE) -24%, VYNE Therapeutics (VYNE) ...
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the BofA Securities 2021 Healthcare Conference. Management is schedu...
Kala Pharmaceuticals, Inc. (KALA) Q1 2021 Earnings Conference Call May 05, 2021, 08:00 ET Company Participants Niranjan Kameswaran - SVP, Strategy Mark Iwicki - Chairman, President & CEO Todd Bazemore - COO Mary Reumuth - CFO & Treasurer Conference Call Participants Andreas Argyrides ...
Kala Pharmaceuticals (KALA): Q1 GAAP EPS of -$0.49 misses by $0.01.Revenue of $3.27M (+205.6% Y/Y) misses by $0.23M.Press Release For further details see: Kala Pharmaceuticals EPS misses by $0.01, misses on revenue
-- Achieved $3.3 Million in Net Revenue in First Quarter -- -- Launched EYSUVIS® and Expanded Commercial Coverage to More than 69 Million Commercial Lives -- -- New Credit Facility Provides up to $125M -- -- Cash Runway Projected for at Least Two Years -- ...
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report first quarter 2021 financial results on Wednesday, May 5, 2021. Manageme...
Kala Pharmaceuticals’ Eysuvis, a corticosteroid-based drug, was approved for both signs and symptoms of dry eye disease last year and sale calls began on Jan 4th 2021. The market uptake of Eysuvis has been good so far and will likely speed up further after more insurers come on...
Kala Pharmaceuticals has had a torrid time growing sales of its first approved ocular therapy Inveltys, for postoperative pain, which earned just $6.1m in FY20. In October last year, Kala won approval for Eysuvis, a corticosteroid treatment for short-term symptoms of dry eye disease -...
News, Short Squeeze, Breakout and More Instantly...
Kala Pharmaceuticals Inc. Company Name:
KALA Stock Symbol:
NASDAQ Market:
Kala Pharmaceuticals Inc. Website:
2024-07-27 11:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 30.9% to $0.6 on volume of 558,931,853 shares NVIDIA Corporation (NVDA) fell 1.9% to $123.99 on volume of 249,243,816 shares Assure Holdings Corp. (IONM) rose 82.8% to $0.424 on vol...
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) is one of today's top gainers. The company's shares have moved 44.91% on the day to $6.55. Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus pe...